255 related articles for article (PubMed ID: 36077262)
21. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.
Guengerich FP; McCarty KD; Chapman JG
J Biol Chem; 2021; 296():100223. PubMed ID: 33449875
[TBL] [Abstract][Full Text] [Related]
24. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
[TBL] [Abstract][Full Text] [Related]
25. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
26. Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
Foti RS; Rock DA; Pearson JT; Wahlstrom JL; Wienkers LC
Drug Metab Dispos; 2011 Jul; 39(7):1188-95. PubMed ID: 21447734
[TBL] [Abstract][Full Text] [Related]
27. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
28. Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents.
Watanabe A; Takakusa H; Kimura T; Inoue SI; Kusuhara H; Ando O
Drug Metab Dispos; 2017 Mar; 45(3):336-341. PubMed ID: 27974381
[TBL] [Abstract][Full Text] [Related]
29. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
30. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
31. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
[TBL] [Abstract][Full Text] [Related]
32. Interaction of human cytochrome P4503A4 with ritonavir analogs.
Sevrioukova IF; Poulos TL
Arch Biochem Biophys; 2012 Apr; 520(2):108-16. PubMed ID: 22410611
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.
Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2023 May; 20(5):2477-2489. PubMed ID: 36976574
[TBL] [Abstract][Full Text] [Related]
34. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
35. N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.
Jennings GK; Ritchie CM; Shock LS; Lyons CE; Hackett JC
Mol Pharmacol; 2016 Jul; 90(1):42-51. PubMed ID: 27126611
[TBL] [Abstract][Full Text] [Related]
36. Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.
Samuels ER; Sevrioukova IF
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467005
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates.
Kandel SE; Lampe JN
Chem Res Toxicol; 2021 Apr; 34(4):1150-1160. PubMed ID: 33821626
[TBL] [Abstract][Full Text] [Related]
38. Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.
Toupin N; Steinke SJ; Nadella S; Li A; Rohrabaugh TN; Samuels ER; Turro C; Sevrioukova IF; Kodanko JJ
J Am Chem Soc; 2021 Jun; 143(24):9191-9205. PubMed ID: 34110801
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
Guo X; Li W; Li Q; Chen Y; Zhao G; Peng Y; Zheng J
Chem Res Toxicol; 2019 Sep; 32(9):1791-1800. PubMed ID: 31414593
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.
Kumar S; Kumar A
Alcohol Clin Exp Res; 2011 Dec; 35(12):2121-7. PubMed ID: 21682753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
